Skip to main content
Geoffrey Shapiro, MD, Oncology, Boston, MA

Geoffrey Ira Shapiro MD PhD

Oncology•Boston, MA

Hematologic Oncology, Thoracic Cancer

Senior Vice President, Developmental Therapeutics; Clinical Director, Center for DNA Damage and Repair; Institute Physician, Dana-Farber Cancer Institute; Co-Leader, Developmental Therapeutics Program, Dana-Farber/Harvard Cancer Center; Professor of Medicine, Harvard Medical School

Join to view full profile

  • 450 Brookline Ave M446Boston, MA 02215

  • Phone+1 617-632-4942

  • Fax+1 617-632-1977

Dr. Shapiro is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Shapiro's full profileAlready have an account?

Summary

  • Geoffrey Shapiro, MD, PhD, is an experienced oncologist based in Boston, MA, specializing in Developmental Therapeutics and early phase oncology clinical trials. He completed his internal medicine residency at Beth Israel Deaconess Medical Center and medical oncology fellowship at Dana-Farber Cancer Institute. Dr. Shapiro directed the Phase 1 Program at Dana-Farber for 13 years and currently serves as Senior Vice President, Developmental Therapeutics. His clinical experience includes all solid tumors, including BRCA-associated cancers, as well as thoracic and gastrointestinal cancers. Aside from his clinical practice, Dr. Shapiro is an accomplished researcher, having published a range of studies related to cell cycle and DNA repair therapeutics in respected publications, and leads multiple clinical trials. He has been honored multiple times for his contributions to oncology, including the George P. Canellos Award for Excellence in Clinical Investigation and Patient Care from Dana-Farber, the Michaele Christian Early Drug Development Award from the National Cancer Institute, and the 2024 Distinguished Investigator of the Year award from the Massacusetts Society of Clinical Oncology (MASCO).

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1991 - 1994
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1988 - 1991
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1988
  • Weill-Cornell Graduate School of Medical Sciences
    Weill-Cornell Graduate School of Medical SciencesPh.D., 1987
  • Columbia College, Columbia University
    Columbia College, Columbia UniversityB.A., Biochemistry, Magna Cum Laude, 1981

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1991 - 2026
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
  • CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors  
    David S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine
  • Institutional Implementation of Clinical Tumor Profiling on an Unselected Cancer Population  
    Khanh Do, Lauren L Ritterhouse, William C Hahn, Geoffrey I Shapiro, Barrett J Rollins, Neal I Lindeman, Alanna Church, Geoffrey R Oxnard, Bruce E Johnson, Frank C Kuo,..., The Journal of Clinical Investigation
  • Clinical development of the CDK4/6 inhibitors abemaciclib and ribociclib in breast cancer  
    Barroso-Sousa, Shapiro GI and Tolaney S.M., Breast Care, 1/1/2016

Books/Book Chapters

  • PARP inhibitors for cancer therapy. 
    Chapter: Disruption of DNA repair by cell cycle and transcriptional CDK inhibition. 
    Page 413 - 430Cornell L, Johnson N, Shapiro GIEditors: NJ Curtin and RA Sharma.Humana Press2015

Abstracts/Posters

  • GSK525762, a selective bromodomain (BRD) and extra termina protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with...
    O’Dwyer PJ, Piha-Paul S, French C, Harward S, Ferron-Brady G, Wu Y, Barbash O, Wyce A, Annan M, Horner T, Parr NJ, Prinjha RK, Carpenter C, Shapiro G, Dhar A, Hann C, Proc Amer Assoc Cancer Res, 1/1/2016
  • Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus.
    George S, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Wagner AJ, Merriam P, Morgan JA, Rodig SJ, Hodi SF, Shapiro G, Demetri GD, J Clin Oncol, 1/1/2016
  • In vivo synergism between PARP inhibitor olaparib and HSP90 ihibitor AT13387 in high-grade serous ovarian cancer patient-derived xenografts.
    Konstantinopoulos P, Palakurthi S, Zeng Q, Zhou S, Liu JF, Ivanova E, Paweletz C, Kommajosyula N, D’Andrea AD, Shapiro G, Matulonis UA, J Clin Oncol, 1/1/2016

Lectures

  • Developmental Therapeutics and Tumor Biology (Nonimmuno) 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
  • Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Other

  • Small molecule inhibitors of cyclin-dependent kinases. In: M.V. Blagosklonny, editor. Cell Cycle Checkpoints and Cancer. 
    Shapiro GI, Landes Bioscience
    Georgetown, TX - 1/1/2001
  • Thesis: Influenza virus gene expression: viral RNA replication in vivo and in vitro. 
    Shapiro GI, Weill-Cornell Graduate School of Medical Sciences,
    Cornell University - 1/1/1987

Press Mentions

  • Dana-Farber Researchers Identify Interventions for Breast and Colorectal Cancer That Could Redefine Standard of Care
    Dana-Farber Researchers Identify Interventions for Breast and Colorectal Cancer That Could Redefine Standard of CareMay 23rd, 2025
  • Novobiocin Attacks BRCA-Mutated Cancer Cells from Within and Without, Study Shows
    Novobiocin Attacks BRCA-Mutated Cancer Cells from Within and Without, Study ShowsMarch 14th, 2023
  • Computer Platform Helps Match Patients with Cancer to Trials of Targeted Therapy
    Computer Platform Helps Match Patients with Cancer to Trials of Targeted TherapyOctober 12th, 2022

Grant Support

  • Macrophage-directed strategies for BRCA-associated breast cancerBRIGHAM AND WOMEN'S HOSPITAL2026–2031
  • Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast CancerDANA-FARBER CANCER INST2013–2030
  • Genetically engineered mouse model to improve therapy of NUT carcinomaBRIGHAM AND WOMEN'S HOSPITAL2023–2028
  • Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancersDANA-FARBER CANCER INST2022–2027
  • Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTNDANA-FARBER CANCER INST2014–2027

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Geoffrey Shapiro, Dr. Geoffrey Shapiro, MD, Dr. G Shapiro, Dr. Geoffrey Ira Shapiro